[go: up one dir, main page]

WO2016167545A1 - Micro-aiguille soluble contenant un ingrédient pour réguler la libération de neurotransmetteurs - Google Patents

Micro-aiguille soluble contenant un ingrédient pour réguler la libération de neurotransmetteurs Download PDF

Info

Publication number
WO2016167545A1
WO2016167545A1 PCT/KR2016/003845 KR2016003845W WO2016167545A1 WO 2016167545 A1 WO2016167545 A1 WO 2016167545A1 KR 2016003845 W KR2016003845 W KR 2016003845W WO 2016167545 A1 WO2016167545 A1 WO 2016167545A1
Authority
WO
WIPO (PCT)
Prior art keywords
microneedle
skin
calcium channel
neurotransmitters
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2016/003845
Other languages
English (en)
Korean (ko)
Inventor
강내규
이현종
장윤희
김태윤
김기영
심우선
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG H&H Co Ltd
Original Assignee
LG Household and Health Care Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020150144855A external-priority patent/KR102203633B1/ko
Priority claimed from KR1020150159978A external-priority patent/KR102099326B1/ko
Priority to HK18107180.5A priority Critical patent/HK1247575A1/zh
Application filed by LG Household and Health Care Ltd filed Critical LG Household and Health Care Ltd
Priority to CN201680019249.4A priority patent/CN107427474A/zh
Priority to JP2017553096A priority patent/JP6784442B2/ja
Priority to US15/566,094 priority patent/US10391289B2/en
Priority to EP16780268.5A priority patent/EP3284506B1/fr
Priority to PL16780268T priority patent/PL3284506T3/pl
Publication of WO2016167545A1 publication Critical patent/WO2016167545A1/fr
Anticipated expiration legal-status Critical
Priority to US16/516,867 priority patent/US11577063B2/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin

Definitions

  • the present invention relates to soluble microneedles and relates to skin administration systems capable of delivering to the skin a substance that controls the release of neurotransmitters.
  • the stratum corneum of the skin is a brick structure consisting of keratin-rich keratinocytes, and a mortar filled with lipids such as ceramide, fatty acids, or waxes between the keratinocytes. It consists of a structure. This structure acts as a barrier and has a very low material permeability. Only low molecular structure components of 500 Da or less can be delivered into the skin by diffusion, and only substances with good lipid affinity can pass through the skin.
  • the release of neurotransmitters is caused by the formation of a pathway between the two boundaries after the synaptic vesicle and the presynaptic membrane are fused at the nerve terminal containing the neurotransmitter.
  • SNARE proteins a protein complex consisting of the vesicle protein VAMP (synaptobrevin) and the plasma membrane binding proteins Syntaxin 1a and SNAP-25, provide a fundamental force for the fusion of synaptic vesicles with the entire synaptic membrane. .
  • the neurotransmitter excretion pathway is opened by membrane fusion between synaptic vesicles and the synaptic epithelium, t-SNARE and vesicles (a complex of syntaxin 1a protein and SNAP-25 protein attached to the target membrane). This is the result of the operation of v-SNARE attached to the vesicle.
  • t-SNARE a complex of syntaxin 1a protein and SNAP-25 protein attached to the target membrane.
  • calcium channel blocker (Calcium channel blocker) is known to reduce the contraction of the muscle by acting to inhibit the calcium, which is an important factor for contracting the muscle to enter the muscle vascular fiber cells. Facial movements are caused by the contraction of muscles under the skin, allowing different muscles to move different parts of the face.
  • the calcium channel blocker had to be delivered to the muscle layer, so that the simple application of cosmetics had difficulty in absorbing the drug to the muscle layer.
  • Injecting calcium channel blockers into the skin can be limited to use by individuals because they involve pain and require treatment, and side effects can occur because oral administration affects the whole body.
  • the problem to be solved by the present invention is to provide a soluble microneedle excellent skin penetration amount.
  • soluble microneedle It impregnates soluble microneedle with components that have excellent wrinkle improvement by blocking neurotransmission and are applied to skin without pain by microneedle and applied to skin, while microneedles are dissolved by moisture in skin and deliver drugs into skin. To provide a soluble microneedle.
  • the present invention allows the effective needle to be delivered into the skin while the fine needle is dissolved by the water in the skin.
  • the present invention aims to reduce the release of neurotransmitter by the active ingredient delivered into the skin to relax the muscles to improve wrinkles and facial lines and to suppress pain.
  • the present invention is to solve the problem that the solubility is not good in the general cosmetic composition limited the amount of polyphenols used, improve the solubility of polyphenols to provide a skin delivery system that can be applied to the skin.
  • the present invention provides a microneedle comprising a component for controlling the release of neurotransmitter, preferably the microneedle is a soluble microneedle.
  • the component that modulates the release of neurotransmitters may be i) polyphenols or derivatives thereof, ii) calcium channel blockers, or iii) mixtures thereof.
  • the microneedle preferably contains the microneedle containing a component for controlling the release of neurotransmitter, and has a wrinkle improvement effect.
  • the material forming the microneedles may be dissolved or biodegradable in the skin, and the microneedles are dissolved or decayed when the microneedles are applied to the skin, thereby releasing components that control the release of the neurotransmitter, and the release of the neurotransmitter. Ingredients that regulate the ability to be delivered to the skin stably.
  • the components included in the microneedle include polyphenols or derivatives thereof.
  • the present inventors have studied a variety of administration systems, and as mentioned above, any system has a low solubility, and thus the application of the polyphenol to the general cosmetics is limited only by application to the skin.
  • the inventors have made a surprising invention that, after various efforts, by containing polyphenols in the soluble microneedle in the skin, it can effectively reduce the transmission of neurotransmitters to exhibit wrinkle improvement.
  • microneedles must be soluble in the skin, and hyaluronic acid, sodium carboxymethyl cellulose (Na-CMC, Sodium carboxymethyl cellulose) and vinyl blood to form soluble microneedles.
  • Water-soluble polymers such as a rollidone-vinylacetate copolymer, poly vinyl alcohol, and poly vinyl pyrrolidone; Sugars such as xylose, sucrose, maltose, lactose, trehalose and the like; Or mixtures thereof may be used.
  • the microneedle according to the present invention may further include a plasticizer, a surfactant, a preservative, an anti-inflammatory agent and the like in addition to the above-mentioned components forming the microneedle.
  • plasticizer for example, polyols such as ethylene glycol, propylene glycol, dipropylene glycol, dipropylene glycol, butylene glycol, glycerin, etc. may be used alone. Or may be used in admixture.
  • polyols such as ethylene glycol, propylene glycol, dipropylene glycol, dipropylene glycol, butylene glycol, glycerin, etc. may be used alone. Or may be used in admixture.
  • the microneedle of the present invention controls the neurotransmitter discharge, and may contain 0.01 to 10% by weight, more preferably 0.1 to 5% by weight of polyphenol having a wrinkle improvement effect relative to the total weight of the microneedle. have.
  • the microneedle may comprise a high content of polyphenol components and may provide a polyphenol skin delivery system in which the amount delivered to the skin is significantly increased compared to formulations of common cosmetic compositions.
  • the polyphenol component was poorly soluble, so that the amount contained in the cosmetic composition was extremely low, but the microneedle of the present invention was extremely low in water so that it could be delivered to the skin by applying a high content to the microroll needle without precipitation of the polyphenol component.
  • the polyphenols are camphorol, quercetin, myricetin, luteolin, delchinidine, cyanidin, butane, ellagic acid, ampelopsin, hesperydine, aurantinidin, europinidin, pella May be at least one selected from the group consisting of Peargonidin, Malvidin, Peonidin, Peunidin, Petunidin, and Rossinidin, and derivatives thereof. May be any one or more selected from the group consisting of ampelopsin, hesperidin or derivatives thereof.
  • Derivatives of the polyphenols herein are free form (free acid or base form) and all prodrugs, polymorphs, hydrates, solvates, tautomers, steric Unless otherwise specified, isomers include all pharmaceutically acceptable forms as described above and are used in the sense to include all active forms of the compounds.
  • the microneedle containing polyphenols inhibits the formation of SNARE complexes and inhibits membrane fusion. As a result, the microneedles inhibit the release of neurotransmitters such as acetylcholine. Shrinkage can be suppressed.
  • the present invention provides a microneedle patch system for administration (delivery) of polyphenols or derivatives thereof to which the microneedle is attached.
  • microneedles of the present invention can be prepared by a method of manufacturing conventional soluble microneedles in the art, and the production method is not particularly limited.
  • the microneedle manufacturing method of the present invention (S1) is a solution containing a component (for example, calcium channel blocker, polyphenol or derivatives thereof, or mixtures thereof) to control the release of neurotransmitters.
  • Manufacturing step (S2) injecting the solution into the microneedle mold; And (S3) drying and separating the microneedle from the mold.
  • a component for example, calcium channel blocker, polyphenol or derivatives thereof, or mixtures thereof
  • the present invention also provides a method for administering the skin of polyphenols having improved solubility and improved skin delivery, characterized by using the microneedle according to the present invention.
  • the present invention provides a wrinkle improvement use of the microneedle containing the polyphenol having the effect of improving the wrinkles, and control the neurotransmitter discharge.
  • the present invention provides microneedles containing polyphenols and inhibiting SNARE complex formation.
  • the present invention provides a skin wrinkle improvement of the microneedle containing a component for controlling the release of neurotransmitter.
  • the present invention provides a microneedle containing a calcium channel blocker, and has an effect of improving wrinkles or improving facial contour through muscle relaxation. More preferably, the material forming the microneedle is dissolved in the skin to release or disintegrate the calcium channel blocker upon application of the microneedle to the skin, and the calcium channel blocker can be stably delivered to the skin.
  • the inventors have studied a variety of dosage systems and have, after many efforts, contained calcium channel blockers in soluble microneedles in the skin, effectively reducing the delivery of neurotransmitters, inhibiting muscle contraction, and improving skin wrinkles or facial
  • the contours have been improved to create an amazing invention that can produce lifting effects.
  • microneedles must be soluble in the skin, and hyaluronic acid, sodium carboxymethyl cellulose (Na-CMC, Sodium carboxymethyl cellulose) and vinyl blood to form soluble microneedles.
  • Water-soluble polymers such as a rollidone-vinylacetate copolymer, poly vinyl alcohol, and poly vinyl pyrrolidone; Sugars such as xylose, sucrose, maltose, lactose, trehalose and the like; Or mixtures thereof may be used.
  • the microneedle according to the present invention may further include a plasticizer, a surfactant, a preservative, an anti-inflammatory agent and the like in addition to the above-mentioned components forming the microneedle.
  • plasticizer for example, polyols such as ethylene glycol, propylene glycol, dipropylene glycol, dipropylene glycol, butylene glycol, glycerin, etc. may be used alone. Or may be used in admixture.
  • polyols such as ethylene glycol, propylene glycol, dipropylene glycol, dipropylene glycol, butylene glycol, glycerin, etc. may be used alone. Or may be used in admixture.
  • the microneedle of the present invention contains 0.0001 to 20% by weight of calcium channel blocker to the total weight of the microneedle preparation solution, and more preferably 0.001 to control the release of neurotransmitter and control skin muscle contraction. To 5% by weight.
  • a "calcium channel blocker” is also referred to as a calcium antagonist and refers to a substance that blocks calcium from entering the muscle and thereby inhibits muscle contraction.
  • the calcium channel blocker is at least one member of the group consisting of copper gluconate, zinc gluconate, magnesium sulfate, magnesium gluconate and magnesium aspatate.
  • Organometallic compounds selected; At least one dihydropyridine calcium channel blocker selected from the group consisting of amlodipine, lercanidipine, felodipine, nifedipine, nicardipine, isradinine, nisoldipine and pharmaceutically acceptable salts thereof; Phenylalkylamine based calcium channel blockers including verapamil; Benzothiapine-based calcium channel blockers including dithiazem; And N-type calcium channel blockers selected from the group consisting of gabapentinoids and zinconotides; It may be any one or more selected from the group consisting of, any material capable of muscle relaxation by blocking calcium flowing into the calcium channel may be included, and the type is not particularly limited.
  • the calcium channel blocker may preferably use magnesium gluconate.
  • the present invention provides a microneedle patch system, preferably a microneedle patch system for calcium channel blocker administration (for delivery), comprising a component for controlling the release of neurotransmitters to which the microneedle is attached.
  • the present invention also provides a method of skin administration of a component for controlling the release of neurotransmitters with improved skin delivery rate, preferably a method of skin administration of a calcium channel blocker, characterized in using the microneedle according to the invention.
  • the present invention provides a microneedle for facial muscle relaxation and its facial muscle relaxation uses, including a microneedle containing a component for controlling the discharge of the neurotransmitter.
  • the facial muscle relaxation is a concept including the use of improving the wrinkles by inhibiting the muscle contraction of the skin, the use of improving the contour of the face, the use of having a lifting effect by preventing the sagging of the skin.
  • a method of skin administration of a component for controlling the release of neurotransmitters using the microneedle of the present invention preferably a method of skin administration of a calcium channel blocker for wrinkle improvement.
  • the present invention provides a microneedle having a skin wrinkle improvement effect.
  • the present invention provides a microneedle for skin administration, which can improve the skin permeation efficiency of the polyphenol having a wrinkle improvement effect.
  • the present invention also provides a method for administering the skin of a component that modulates the release of neurotransmitter, characterized by using such microneedles.
  • the present invention provides a microneedle having a skin wrinkle improvement effect or facial contour line improvement effect.
  • the present invention can transmit the active ingredient into the skin without pain by the microneedle.
  • the present invention can inhibit the calcium channel of nerve cells to block the release of neurotransmitters to relax the muscles to improve wrinkles and facial lines.
  • the soluble microneedle may be prepared by a solution casting method, and the solution may be cast into a mold to fill a fine mold with a vacuum and / or centrifuge, followed by drying.
  • the material forming the microneedle structure general synthetic and natural water-soluble polymers may be used.
  • Figure 2 shows a Franz diffusion cell for evaluating the drug release behavior of the microneedle according to the present invention.
  • 3 exemplarily shows a polyphenol having a Botox-like effect of the present invention.
  • Myricetin, delchinidine, cyanidin, camphorol, quercetin, pisetin, butane, luteolin, ellagic acid, EGCG (Epigallocatechin gallate), ampfellopsin, hesperidin and derivatives thereof can be used.
  • Figure 4 shows the results confirmed the inhibition of SNARE formation of camphorol, myricetin, and ampelopsin.
  • Figure 5 is a graph showing the results of comparing the ampelopsin content in pig skin and acceptor solution.
  • Figure 6 is a graph showing the results of confirming the wrinkle improvement effect of the Amfellopsin cream and Amfellopsin microneedle in the human body.
  • Fig. 7 shows the results of confirming the muscle contraction inhibitory effect of camphorol, myricetin, and ampelopsin.
  • Figure 9 shows the results of measuring the inhibitory effect of In Vitro muscle contraction of magnesium gluconate. After incubation of myocytes and neuroblasts in vitro and treatment of magnesium gluconate by concentration, the results show that the number of muscle contractions decreases after 10 minutes.
  • Figure 10 graphically shows the wrinkle improvement index of magnesium gluconate cream and magnesium gluconate microneedle.
  • Soluble Micro Needle is manufactured by solution casting method.
  • the solution is cast into a mold, filled with liquid in a micro mold by vacuum or centrifuge, and then dried. At this time, general synthetic and natural water-soluble polymers are used to form the micro needle structure. .
  • microneedle having the composition of Table 1.
  • Dissolve Hyaluronic acid (Oligo-HA TM), Sodium carboxymethyl cellulose (Na-CMC) and Trehalose in purified water, and then use a solution of Glycerin, PEG-40 hydrogenated castor oil (HCO-40 TM) and Amfellopsin (10% Amfellopsin, DPG 90). %) was added to prepare an amfellopsin solution (DPG: Dipropylene glycol).
  • the prepared polyphenol dispersion solution was cast on a silicone micro needle mold, and then centrifuged at 3,000 rpm for 10 minutes to fill the liquid in the micro mold.
  • the manufacturing process is shown in FIG.
  • the polyphenol was impregnated and compared with a general oil-in-oil type cream as a comparative example.
  • Amphelopsin release from the microneedle prepared above was evaluated using a Franz diffusion cell equipped with pig skin (see FIG. 2).
  • As an aqueous solution (acceptor solution) was used a PBS solution containing 30% by weight of DPG.
  • the cream containing ampelopsin was minimal in permeation through the skin, but the ampoulescin impregnated in the Micro Needle penetrated directly into the skin by the needle, and the permeation amount was higher than that of the cream.
  • Cream containing ampelopsin was about 1ug permeated through the skin, but the amount was small.However, polyphenol impregnated in the microneedle penetrated directly into the skin by the needle, and its permeation amount was 13ug or more, which was 13 times higher than the cream. Skin permeation amount is shown. The result is shown in FIG.
  • ampellopsin-impregnated microneeedle showed more than 5 times better improvement, and it was confirmed that ampelopsin was effectively penetrated into the skin by the microneedle, resulting in a high wrinkle improvement effect.
  • SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
  • Camperol, myricetin and ampelopsin have all been found to effectively inhibit the SNARE complex in a concentration dependent manner. As a result, it was confirmed that the activity of inhibiting SNARE complex formation at low concentrations of camphorol and ampelopsin was higher than that of myricetin. Inhibition of SNARE formation of myricetin, ampfellopsin (dihydroxymyricetin), camphorol, and A440 was confirmed and shown in FIG. 4. (Cell line: C2C12 (muscle cell) + NG108-15 (nerve cell) condition, concentration: ppm)
  • C2C12 cells were cultured in DMEM medium containing 10% fetal calf serum and 1% antibiotics on plates. Neuroblasts were then further co-cultured on the same plate. After that, when the cell contraction of C2C12 cells starts, measure the number of contractions of C2C12 cells for 30 seconds, remove all the medium, wash them three times with PBS, and add the calf serum-containing medium and 50 ppm of polyphenolic compound for 2 hours. I was. Afterwards, the contraction frequency of C2C12 cells was measured again for 30 seconds to confirm the degree of muscle contraction inhibition.
  • Camperol, myricetin and ampelopsin inhibited the release of neurotransmitters from neurons, reducing the number of C2C12 cell contractions. Among them, the effect of inhibiting the release of amfellopsin and camphorol compared to myricetin was relatively high. The result is shown in FIG.
  • a cosmetic composition comprising ampelopsin of the present invention
  • it may include less than 0.5% (PEG400 5%, based on 70% water) ampelopsin
  • the microneedle manufactured by the method of manufacturing the microneedle of the present invention Amfellopsin content can be increased to around 5% of the microneedle dry weight.
  • a product containing a high concentration of polyphenols can be produced.
  • Soluble microneedle is manufactured by the solution casting method, the solution was cast by casting the mold to the mold by vacuum or centrifuge the liquid was prepared by drying.
  • the magnesium gluconate dispersion solution was cast into a silicone microneedle mold, and then centrifuged at 3000 rpm for 10 minutes to fill the micro mold with liquid. After the solution was filled and dried for 3 hours in a drying oven (70 °C), the microneedle was separated from the silicone mold by using an adhesive film.
  • magnesium gluconate was impregnated into the cream of the general oil-in-water emulsion as an example.
  • magnesium gluconate content of pig skin tissue and acceptor solution over time was measured by Liquid Chromatography. Magnesium gluconate cream was applied to porcine skin or microneedle impregnated with magnesium gluconate was used to compare skin penetration of magnesium gluconate over time.
  • Cream containing magnesium gluconate is less than about 1 ug permeated through the skin, but the amount of magnesium gluconate impregnated in the microneedle penetrates directly into the skin by the needle, and the permeation amount is 20 ug or more, about 20 times or more. It showed a higher skin penetration than the cream. The results are shown in FIG.
  • the present invention can be used for cosmetics, pharmaceuticals for skin wrinkle improvement.
  • the microneedle of the present invention can expect excellent skin wrinkle reduction effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un système d'administration par voie cutanée capable d'améliorer l'efficacité de l'administration par voie cutanée d'un ingrédient pour réguler la libération de neurotransmetteurs et, en particulier, une micro-aiguille contenant un ingrédient pour réguler la libération de neurotransmetteurs.
PCT/KR2016/003845 2015-04-13 2016-04-12 Micro-aiguille soluble contenant un ingrédient pour réguler la libération de neurotransmetteurs Ceased WO2016167545A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL16780268T PL3284506T3 (pl) 2015-04-13 2016-04-12 Rozpuszczalna mikroigła zawierająca składnik do kontroli uwalniania neuroprzekaźników
EP16780268.5A EP3284506B1 (fr) 2015-04-13 2016-04-12 Micro-aiguille soluble contenant un ingrédient pour réguler la libération de neurotransmetteurs
HK18107180.5A HK1247575A1 (zh) 2015-04-13 2016-04-12 含有调节神经递质释放的成分的可溶性微针
CN201680019249.4A CN107427474A (zh) 2015-04-13 2016-04-12 含有调节神经递质释放的成分的可溶性微针
JP2017553096A JP6784442B2 (ja) 2015-04-13 2016-04-12 神経伝達物質の排出を調節する成分が含まれた溶解性マイクロニドル
US15/566,094 US10391289B2 (en) 2015-04-13 2016-04-12 Soluble microneedle containing ingredient for controlling release of neurotransmitters
US16/516,867 US11577063B2 (en) 2015-04-13 2019-07-19 Soluble microneedle containing ingredient for controlling release of neurotransmitters

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR20150052043 2015-04-13
KR10-2015-0052043 2015-04-13
KR10-2015-0052575 2015-04-14
KR20150052575 2015-04-14
KR1020150144855A KR102203633B1 (ko) 2015-04-14 2015-10-16 칼슘채널 차단제 전달용 용해성 미세바늘
KR10-2015-0144855 2015-10-16
KR10-2015-0159978 2015-11-13
KR1020150159978A KR102099326B1 (ko) 2015-04-13 2015-11-13 폴리페놀 전달용 용해성 마이크로니들

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/566,094 A-371-Of-International US10391289B2 (en) 2015-04-13 2016-04-12 Soluble microneedle containing ingredient for controlling release of neurotransmitters
US16/516,867 Continuation US11577063B2 (en) 2015-04-13 2019-07-19 Soluble microneedle containing ingredient for controlling release of neurotransmitters

Publications (1)

Publication Number Publication Date
WO2016167545A1 true WO2016167545A1 (fr) 2016-10-20

Family

ID=57126565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/003845 Ceased WO2016167545A1 (fr) 2015-04-13 2016-04-12 Micro-aiguille soluble contenant un ingrédient pour réguler la libération de neurotransmetteurs

Country Status (1)

Country Link
WO (1) WO2016167545A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10821084B2 (en) * 2018-01-31 2020-11-03 Remy Biosciences, Inc. Dihydromyricetin compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100901074B1 (ko) * 2008-09-03 2009-06-03 성균관대학교산학협력단 신경전달물질 배출을 조절하기 위한 폴리페놀 화합물
KR20100094983A (ko) * 2007-11-02 2010-08-27 애크럭스 디디에스 피티와이 리미티드 경피 전달 시스템
KR101041698B1 (ko) * 2002-07-11 2011-06-14 알러간, 인코포레이티드 경피성 보툴리눔 독소 조성물
KR20130135819A (ko) * 2010-06-09 2013-12-11 리포텍 에스.에이. 피부 항노화 처리
KR20140143416A (ko) * 2012-04-05 2014-12-16 히사미쓰 세이야꾸 가부시키가이샤 천자 장치 및 그 제조 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101041698B1 (ko) * 2002-07-11 2011-06-14 알러간, 인코포레이티드 경피성 보툴리눔 독소 조성물
KR20100094983A (ko) * 2007-11-02 2010-08-27 애크럭스 디디에스 피티와이 리미티드 경피 전달 시스템
KR100901074B1 (ko) * 2008-09-03 2009-06-03 성균관대학교산학협력단 신경전달물질 배출을 조절하기 위한 폴리페놀 화합물
KR20130135819A (ko) * 2010-06-09 2013-12-11 리포텍 에스.에이. 피부 항노화 처리
KR20140143416A (ko) * 2012-04-05 2014-12-16 히사미쓰 세이야꾸 가부시키가이샤 천자 장치 및 그 제조 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3284506A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10821084B2 (en) * 2018-01-31 2020-11-03 Remy Biosciences, Inc. Dihydromyricetin compositions

Similar Documents

Publication Publication Date Title
US11577063B2 (en) Soluble microneedle containing ingredient for controlling release of neurotransmitters
KR102445155B1 (ko) 폴리페놀 전달용 용해성 마이크로니들
US11000472B2 (en) Soluble microneedle for delivering poorly-soluble drug
WO2016163753A1 (fr) Micro-aiguille soluble pour administrer des protéines ou des peptides
WO2018212592A1 (fr) Timbre percutané à micro-aiguilles contenant du donépézil
KR20100027139A (ko) 5－메틸-1－페닐기-2－(1ｈ)－피리돈 함유 첩부제
WO2016163752A1 (fr) Micro-aiguille soluble pour l'administration de médicaments faiblement solubles
WO2016167545A1 (fr) Micro-aiguille soluble contenant un ingrédient pour réguler la libération de neurotransmetteurs
WO2019004543A1 (fr) Composition cosmétique de peptide régulateur de neurotransmetteur à perméabilité transdermique améliorée
TWI722006B (zh) 含有調節神經遞質釋放的成分的可溶性微針
EP1987819B1 (fr) Forme enrichie injectable de Flupirtine
WO2019245332A1 (fr) Composition pharmaceutique pour traiter une plaie ou activer la peau, contenant du bêta-glucane, de la glycitine et de la 4', 6,7-triméthoxyisoflavone
WO2021261926A1 (fr) Injection à action prolongée pour le traitement de la démence
WO2020222552A1 (fr) Composition pharmaceutique, comprenant de la 6-diazo-5-oxo-l-norleucine, pour le traitement d'une maladie cutanée inflammatoire
WO2024237528A1 (fr) Nanosupport ciblé pour cicatrisation de plaie, et son procédé de fabrication
KR20170032808A (ko) 멘톨 또는 멘톨 유도체를 포함하는 용해성 미세바늘 패치
WO2020122681A1 (fr) Composition comprenant du dutastéride
WO2023090781A1 (fr) Composition destinée à prévenir et améliorer la rosacée cutanée comprenant de l'acide isochlorogénique ou un sel de celui-ci en tant que principe actif
WO2025198324A1 (fr) Nanomicelles à auto-assemblage de polymère ciblé sur des cellules, et leur procédé de préparation
WO2016159532A2 (fr) Composition de vernis à ongles contenant du ciclopirox
WO2024253345A1 (fr) Composition d'hydrogel pour le traitement de la dermatite atopique comprenant du sucre naturel
WO2025084725A1 (fr) Peptide ayant une activité de blanchiment de la peau et ses utilisations
WO2021172870A1 (fr) Nouveaux peptides pour la prévention ou le traitement de la dermatite atopique
KR20170000740A (ko) 리그닌퍼옥시다아제 전달용 용해성 미세바늘 패치

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16780268

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017553096

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15566094

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE